Cell therapy startup repairing brain tissue seeks advisor with capability to invest

This company is pioneering a cell-based therapy to repair damaged brain tissue, starting with treatment for mesial temporal lobe epilepsy with hippocampal sclerosis. They engineer transplantable hippocampal tissue from stem cells, using a proprietary biomatrix and minimally invasive delivery methods. The approach aims to rebuild functional brain circuits rather than simply remove damaged areas. Backed by a team of leading neuroscientists and biotech founders, the company is currently in preclinical development and targeting first-in-human trials within 3.5 years.